| Home | Search Abstracts | Browse Sessions | Program Committee | Conference Webcasts | Contact Us |
|
Session 32
Oral Abstracts Clinical and Preclinical Vaccine Studies Wednesday, 4 - 5:30 pm Room 2008 |
| Moderators | Jerry Zack Univ of California, Los Angeles, USA Mark Mulligan Univ of Alabama at Birmingham, USA |
| 4:00 pm 164 | Cross-subtype Immune Responses of HIV-1 Group M Consensus Env Immunogens E A Weaver1, Z Lu1, Y Li2, H-X Liao1, B Ma1, M S Alam1, R M Scearce1, L Sutherland1, J M Decker3, Z Hartman1, A Amalfitano1, G M Shaw3, B T Korber4, B H Hahn2, D C Montefiori1, B F Haynes1, and F Gao*1 1Duke Univ. Med. Ctr., Durham, NC, USA; 2Univ. of Alabama at Birmingham, USA; 3Howard Hughes Med. Inst., Birmingham, AL; and 4Los Alamos Natl. Lab., Los Alamos, NM |
| 4:15 pm 165 | Broad HIV-1 Sensitivity to Neutralization with Vaccine Sera, Monoclonal Antibodies, and HIV+ Plasma and Sera Is a Pan-gp160 Phenomenon Associated with High Fusion Activity and Shortened V1/V2 Rregions T Wrin*, C Chappey, W Huang, and C Petropoulos ViroLogic Inc., South San Francisco, CA, USA |
| 4:30 pm 166 | Containment of SIV Replication in Rhesus Macaques by Vaccine-induced Cytotoxic T Lymphocytes T Matano*1, M Kobayashi1, H Igarashi1, A Takeda1, W Sugiura2, K Mori2, M Kano2, A Iida3, M Hasegawa3, M Miyazawa4, M Yasunami5, A Kimura5, D O'Connor6, D Watkins6, and Y Nagai7 1Univ. of Tokyo, Japan; 2Natl. Inst. of Infectious Diseases, Tokyo, Japan; 3DNAVEC Res. Inc., Tsukuba, Japan; 4Kinki Univ., Osaka, Japan; 5Tokyo Med. and Dental Univ., Japan; 6Univ. of Wisconsin, Madison, USA; and 7Toyama Inst. of Hlth., Japan |
| 4:45 pm 167 | Enhanced Envelope Incorporation in Pseudovirions Produced by Co-transfection with Codon-optimized Envelope Genes D L Kothe*1, E Chertova2, Y Li1, K P Zammit1, J M Decker1, B T Korber3, G M Shaw1, J D Lifson2, and B H Hahn1 1Univ. of Alabama at Birmingham, USA; 2AIDS Vaccine Prgm., SAIC Frederick Inc., MD, USA; and 3Los Alamos Natl. Lab., Los Alamos, NM |
| 5:00 pm 168 | Evaluation of 2 Therapeutic HIV Vaccination Regimens in HAART-treated Primary HIV Infection Subjects following Analytical Treatment Interruption: QUEST PROB3005, a Randomized, Placebo-controlled Study S Kinloch*1, L Perrin2, B Hoen3, F Lampe1, A Phillips1, L Goh4, C Tsoukas5, A Sonnerborg6, B Autran7, J Andersson6, R El Habib8, G Theofan9, N Carter4, D Cooper10, and the QUEST Study Group 1Royal Free and Univ. Coll. Med. Sch., London, UK; 2Geneva Univ. Hosp., Switzerland; 3Hosp. Saint-Jacques, Besancon, France; 4GlaxoSmithKline Res. and Devt., Greenford, UK; 5McGill Univ., Montreal, Canada; 6Karolinska Inst., Stockholm, Sweden; 7Hosp. Pitié-Salpêtrière, Paris, France; 8Aventis Pasteur, Lyon, France; 9Immune Response Corp., Carlsbad, CA, USA; and 10Univ. of New South Wales, Sydney, Australia |
| 5:15 pm 169 | Randomized, Placebo-controlled, Phase1/2a Evaluation of the Safety, Biological Activity and Antiretroviral Properties of an Avipox Virus Vaccine Expressing HIV gag-pol and Interferon- D Cooper*1,10, C Workman1,2, R Puls1,2, M Bloch3, D Baker4, N Bodsworth5, J Anderson6, S Crowe7, M French8, J Hoy9, A Kelleher1, A Aichelberg1, L Ward11, M Law1, and S Emery1 1Natl. Ctr. in HIV Epidemiology and Clin. Res., Sydney, Australia; 2Ground Zero Med. Ctr., Sydney, Australia; 3Holdsworth House Gen. Practice, Sydney, Australia; 4407 Doctors, Sydney, Australia; 5Taylor Square Clin., Sydney, Australia; 6Carlton Clin., Melbourne, Australia; 7Macfarlane Burnet Ctr., Melbourne, Australia; 8Royal Perth Hosp., Australia; 9The Alfred Hosp., Melbourne, Australia; 10St. Vincent's Hosp., Sydney, Australia; and 11Viral Immunotherapeutics Pty. Ltd., Melbourne, Australia |